Company profile
Citius Pharmaceuticals, Inc.
NASDAQ:CTXRBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Phentermine hydrochloride | approved | — | 0 | — |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05348200 | phase2 | completed | 2022-04-22 | 2023-04-20 | Citius Pharmaceuticals, Inc. | Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade Hemorrhoids |
| NCT02689856 | phase2 | completed | 2015-05-01 | 2015-09-01 | Citius Pharmaceuticals, Inc. | Safety and Efficacy of Hydrocortisone and Lidocaine Treatment of Grade I and II Hemorrhoids |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 202088 | NDA | CITIUS PHARMACEUTICALS LLC | ||||
Loading… | ||||||